1. NCHU Institution Repository
  2. 獸醫學院
  3. 獸醫學系所
Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/13901
標題: 偵測分化抗原在犬口腔黑色素瘤的表現及架構一個Melan-A表現質體
Detection of differential antigens expression in canine oral melanomas and construction of Melan-A expression plasmid
作者: 熊祐興
Hsiung, Yu-Hsing
關鍵字: dog;犬;oral melanoma;Melan-A;DNA vaccine;口腔黑色素瘤;Melan-A;DNA vaccine
出版社: 獸醫學系暨研究所
引用: Goldschmidt MH, Dunstan RW, Stannard AA, Tscharner C, Walder EJ, Yager JA. Melanocytic tumors and tumorlike lesions. In: Goldschmidt MH, Dunstan RW, Stannard AA, Tscharner C, Walder EJ, Yager JA, eds. Histologic classification of epithelial and melanocytic tumors of the skin of domestic animals. Armed Forces Institute of Pathology Co, Washington, DC, 38-50, 1998. Liptak JM, Withrow SJ. Oral tumors. In:Withrow SJ, Vail DM, eds. Small animal clinical oncology. 4th ed. Saunders Elsevier Co, Missouri, 455-475, 2007. McKee PH, Calonje E, Granter SR. Cutaneous cyst. In: McKee PH, Calonje E, Granter SR, eds. Pathology of the skin with clinical correlations. 3rd. Elsevier Mosby Co, Philadelphia, 507-509, 2005. Sheehan DC, Hrapchak BB. Pigments and minerals. In: Sheehan DC, Hrapchak BB, eds. Theory and practice of histotechnology. 2nd. CV Mosby Co, St. Louis, MO, 214-232, 1980. Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, MacEwen EG, Vail DM. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother. 55:433-442, 2006. Arenberger P, Arenbergerova M, Gkalpakiotis S, Lippert J, Stribrna J, Kremen J. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma- associated antigens: a novel possible staging method. J Eur Acad Dermatol Venereol. 22:56-64, 2008. Aronsohn MG, Carpenter JL. Distal extremity melanocytic nevi and malignant melanomas in dogs. J Am Anim Hosp Assoc. 26:605-612, 1990. Bateman KE, Catton PA, Pennock PW, Kruth SA. 0-7-21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med. 8:267-272, 1994. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J,Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: phase I trial. Clin Cancer Res. 9:1284-1290, 2003. Bergmen PJ. Canine oral melanoma. Clin Tech Small Anim Pract. 22:55-60, 2007. Bishop PW, Menasce LP, Yates AJ, Win NA, Banerjee SS. An immunophenotypic survey of malignant melanomas. Histopathology. 23:159-166, 1993. Blackwood L, Dobson MA. Radiotherapy of malignant melanomas in dogs. J Am Vet Med Assoc. 209:98-102, 1996. Blessing K, Sanders DSA, Grant JJH. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 32:139-146, 1997. Boria PA, Murry DJ, Bennett PF, Glickman NW, Snyder PW, Merkel BL, Schlittler DL, Mutsaers AJ, Thomas RM, Knapp DW. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc. 224:388-394, 2004. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol. 16:32-40, 1979. van der Bruggen P, van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol. 18:98-104, 2006. Cangul IT, van Garderen E, van der Linde-Sipman JS, van den Ingh TSGAM, Schalken JA. Canine balloon and signet-ring cell melanomas: a histological and immunohistochemical characterization. J Comp Path. 125: 166-173, 2001. Choi C, Kusewitt DF. Comparison of tyrosinase- related protein-2, S-100, and Melan-A immunoreactivity in canine amelanotic melanomas. Vet Pathol. 40: 713-718, 2003. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 54:196-200, 2001. Cochran AJ, Wen DR. S-100 protein as a marker for melanocytic and other tumours. Pathology. 17:340-345, 1985. Cohen-Solal KA, Reuhl KR, Ryan KB, Roberts KG, Chen S. Development of cutaneous amelanotic melanoma in the absence of a functional tyrosinase. Pigment Cell Res. 14:466-474, 2001. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med. 184:1555-1560, 1996. Cotchin E. Tumours in farm animals: a survey of tumours examined at the Royal Veterinary College, London, during 1950-60. Vet Rec. 72:816-823, 1960. Enk AH, Becker JC, Schuler G. Immunotherapy of malignant melanoma- basic principles and novel therapeutic approaches. J. Dtsch Dermatol Ges. 4:635-645, 2006. Ferlay F, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide, IARCPress: Lyon, 2001. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA. 90:11478-11482, 1993. Harvey HJ, MacEwen EG, Braun D, Patnaik AK, Withrow SJ, Jongeward S. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc. 178:580-582, 1981. Hornick JL, Fletcher CDM. PEComa: what do we know so far. Histopathology48:75-82, 2006. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med. 156:1755-1766, 1982. Inoue K, Ohashi E, Kadosawa T, Hong SH, Matsunaga S, Mochizuki M, Nishimura R, Sasaki N. Establishment and characterization of four canine melanoma cell lines. J Vet Med Sci. 66:1437-1440, 2004. Jungbluth AA, Iversen K, Coplan K. T311- an antityrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract. 196:235-242, 2000. Kaldrymidou E, Papaioannou N, Poutahidis TH, Karayannopoulou M, Gruys E, Toliou TH, Tsangaris TH. Malignant lymphoma in nasal cavity and paranalsal sinuses of a dog. J Vet Med. 47:457-462, 2000. Kaufmann O, Koch S, Burghardt J, Audring H, Dietel M. Tyrosinase, Melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 11:740-746, 1998. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S. Recognition o f multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 154:3961-3968, 1995. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. Next generation of immunotherapy for melanoma. J Clin Oncol. 26:3445-3455, 2008. Kligora CJ, Fair KP, Clem MS, Patterson JW. A comparison of melanin bleaching and azure blue counterstaining in the immunohistochemical diagnosis of malignant melanoma. Mod Pathol. 12:1143-1147, 1999. Kosovsky JK, Matthiesen DT, Marretta SM, Patnaik AK. Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Vet Surg. 20:397-401, 1991. Kundig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kuhlcke K, Ohashi PS, Hengartner H, Zinkernagel RM. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 268:1343-1347, 1995. Levy A, Pitcovski J, Frankenburg S, Elias O, Altuvia Y, Margalit H, Peretz T, Golenser J, Lotem M. A melanoma multiepitope polypeptide induces specific CD8+ T cell response. Cell Immunol. 250:24-30, 2007. Liptak JM, Withrow SJ. Oral tumors. In:Withrow SJ, Vail DM, eds. Small animal clinical oncology. 4th ed. Saunders Elsevier Co, Missouri, 455-475, 2007. MacEwen EG, Patnaik AK, Harvey HJ, Hayes AA, Matus R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 4:397-402, 1986. Mai KT, Belanger EC. Perivascular epithelioid cell tumour (PEComa) of the soft tissue. Pathology. 38:4-15, 2006. Miettinen M, Fernandez M, Fransila K, Gatalica Z, Lasota J, Sarlomo-Rikala M. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 25:205-211, 2001. Miller AJ, Mihm Jr. MC. Melanoma. N Engl J Med. 355:51-65, 2006. Morton DL, Mozzillo N, Thompson JF. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 25:474s, 2007. Neefjes JJ, Ploegh HL. Intracellular transport of MHC class II molecules. Immunol Today. 13:179-184, 1992. Nistico P, Capone I, Palermo B, Bello DD, Ferraresi V, Moschella F, Arico E, Valentini M, Bracci L, Cognetti F, Ciccarese M, Vercillo G, Roselli M, Fossile E, Tosti ME, Wang E, Marincola F, Imberti L, Catricala C, Natali PG, Belardelli F, Proietti E. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer. 124:130-139, 2009. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-Lymphocyte Antigen-4 (CTLA-4). Cancer. 110:2614-2627, 2007. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 35:433-444, 2008. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 35:433-444, 2008. Orchard GE. Comparison of immunohistochemical labeling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochems J. 32:475-481, 2000. Orchard GE. Comparison of immunohistochemical labeling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB-45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochems J. 32:475-481, 2000. Ordonez NG, Xiaolong J, Hickey RC. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol. 90:385-390, 1988. Orlow SJ, Hearing VJ, Sakai C, Urabe K, Zhou BK, Silvers WK, Mintz B. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci USA. 92:10152-10156, 1995. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccine. Immunity. 3:165-169, 1995. Piao Y, Guo M, Gong Y. Diagnostic challenges of metastatic spindle cell melanoma on fine-needle aspiration specimens. Cancer. 114:94-101, 2008. Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B, Price GS, Thrall DE. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound. 44:352-359, 2003. Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace LW, Fard A, Kottler SJ. Retrospective study of 338 canine oral melnaomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol. 37:597-608, 2000. Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, Meleo KA, Moore AS. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc. 218:1444-1448, 2001. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA. 91:9519-9523, 1994. Saleh F, Ibrahim G, Dashti H, Romero P, Behbehani A, Al-Sayer H, Asfar S, Dashti A, Renno W, Abdeen S, Klepacek I. Vaccine immunotherapy for a deadly disease like malignant melanoma: where do we stand. Kuwait Med J 37:4-17, 2005. Schwarz PD, Withrow SJ, Curtis CR, Powers BE, Straw RC. Mandibular resection as a treatment for oral cancer in 81 dogs. J Am Anim Hosp Assoc. 27:601-610, 1991. Slingluff Jr CL, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK. Helper T-cell responses and clinical activityh of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 26:4973-4980, 2008. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol. 39:651-678, 2002. Sujatha SEF, Johnson S, Bate J. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology. 26:16-19, 1994. Theon AP, Rodriguez C, Madewell BR. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc. 210:778-784, 1997. tissue. Pathology. 38: 4-15, 2006. Trefzer U, Rietz N, Chen Y. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res. 292:583-589, 2000. Urosevic M, Braun B, Willers J, Burg Gunter, Dummer R. Expression of melanoma-associated antigens in melanoma cell cultures. Exp Dermatol. 14:491-497, 2005. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med. 171:1375-1380, 1990. Wallace J, Matthiesen DT, Patnaik AK. Hemimaxillectomy for the treatment of oral tumors in 69 dogs. Vet Surg. 21:337-341, 1992. Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A. Phase 1 trial of intranodal injection of a Melan-A/ MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother. 31:215-223, 2008. Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest. 102:1258-1264, 1998. Weiss E, Frese K. Tumors of the skin. Bull World Health Organ. 50:79-100, 1974. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science. 247:1465-1468, 1990.
摘要: 
犬黑色素細胞瘤是最常見的口腔腫瘤之一，一旦發生轉移的情形，不管是化學療法或其他現有的治療方式都無法改善其不良的預後。一些可被免疫系統辨認的分化抗原(例如 Melan-A、tyrosinase及gp100)在黑色素細胞瘤當中具有高表現量，這些分化抗原具有使用在免疫療法的潛力。本實驗一開始針對國立中興大學獸醫教學醫院的犬口腔黑色素瘤病例，利用免疫組織化學染色的方式，偵測這些分化抗原表現的情形，這四種免疫組織化學染色所偵測的抗原，皆為100 %的陽性表現，依據免疫組織化學染色的結果，本實驗使用Melan-A基因及一段具有多個抗原決定位(epitope)的序列，來建構一個在獸醫臨床使用的免疫治療物，在本實驗Melan-A成功個從人類黑色素細胞株A375.S2c增幅出，接著分別轉殖到原核及真核表現宰體pET32a及pcDNA3.1當中，且使用Western blot成功偵測到Melan-A的表現，另外一個具有二重複的多抗原決定位序列也藉由PCR增幅出來。

Melanoma is the most common malignant neoplasm of oral cavity in dogs. Metastasis of this cancer is associated with poor durable response to chemotherapy or any other known treatments. Melanoma differential antigens (e.g., Melan-A, tyrosinase and gp100), which are commonly recognized by the immune system, were highly expressed in melanoma lesions. Immunohistochemistry was used to detect the expression of differential antigens of the oral melanomas obtained from the Veterinary Medical Teaching Hospital of National Chung Hsing University. All four immunohistochemistry markers showed 100 % positivity. Based on the results of immunohistochemistry staining, Melan-A was chosen with a multiepitope sequence (gp100 (280V), gp100 (210M), tyrosinase (370D) to generate an immunogenic agent for canine melanoma therapy. In our present study, Melan-A was successfully amplified from human melanoma cell line A375.S2c and was subsequently cloned into pET32a and pcDNA3.1 vector for expression in prokaryotic and mammalian system, respectively. Melan-A expression had also been detected by Western blot. The partial fragment containing two repeats of multiepitope sequence was also obtained by PCR.
URI: http://hdl.handle.net/11455/13901
其他識別: U0005-2207200911041100
Appears in Collections:獸醫學系所

Show full item record
 
TAIR Related Article

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.